Quarterly report pursuant to Section 13 or 15(d)

Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details)

v3.21.2
Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Basic and diluted numerator:    
Net loss attributable to iBio, Inc. stockholders $ (8,939) $ (7,533)
Preferred stock dividends - iBio CMO Preferred Tracking Stock (66) (66)
Deemed dividends - down round of Series A Preferred and Series B Preferred 0 0
Net loss available to iBio, Inc. stockholders $ (9,005) $ (7,599)
Basic and diluted denominator:    
Weighted-average common shares outstanding 217,876 162,442
Per share amount $ (0.04) $ (0.05)